BostonSight’s research team published a ground-breaking study – “Utilizing PROSE as a Drug Delivery Device for Preservative-Free Cyclosporine 0.05% for the Treatment of Dry Eye Disease: A Pilot Study” in the journal Clinical Ophthalmology.
In the study, researchers utilized PROSE as a drug delivery device for preservative-free cyclosporine 0.05% for the treatment of dry eye disease. To our knowledge, this report is the first to ever describe a prospective clinical trial utilizing a pharmaceutical in this manner. This study sets forth the template, concepts, and questions that are open to further investigation in this exciting area of drug delivery.
Ultimately, in the future, we hope this concept and research will lead to an additional ocular management strategy that will utilize the PROSE and SCLERAL platforms as drug delivery devices to open new avenues to improve ocular health and to improve the lives of our patients.
The study authors include staff from BostonSight, Tufts University School of Medicine, and the Department of Mathematical Sciences at Worcester Polytechnic Institute (WPI): Monica Nabil Nakhla, Ria Patel, Estelle Crowley, Yichen Li, Thelge Buddika Peiris, and Daniel Brocks.